Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23299814 | 0.95 | AR (0.36) | KIF11ARSLC22A12GABRA1GABRG2 | |
| SCHEMBL23299815 | 0.94 | SCN9A (0.32) | KIF11SCN9AGABRA1GABRG2GABRB3 | |
| SCHEMBL22156404 | 0.94 | KIF11 (0.34) | KIF11ARSLC22A12GABRA1GABRG2 | |
| SCHEMBL19903532 | 0.88 | KIF11 (0.41) | KIF11ARSLC22A12IMPDH2 | |
| SCHEMBL22156710 | 0.88 | AR (0.36) | KIF11ARSLC22A12GABRA1GABRG2 | |
| SCHEMBL19909531 | 0.87 | NPSR1 (0.32) | KIF11SLC22A12IMPDH2MAPK14 | |
| SCHEMBL23299813 | 0.86 | KIF11 (0.34) | KIF11ARSLC22A12IMPDH2 | |
| SCHEMBL20617042 | 0.86 | KIF11 (0.39) | KIF11ARSLC22A12 | |
| SCHEMBL22157048 | 0.86 | GRM2 (0.34) | SCN9AGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL19913200 | 0.85 | MAPK14 (0.39) | KIF11SLC22A12SCN9AIMPDH2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3635070-B1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2021-04-28 | — | — | EP | disclosed |
| US-20200203628-A1 | ORGANIC MOLECULES FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200203628-A1 | ORGANIC MOLECULES FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | OR10J3, ORC3, OR51E2 | KIF11 4485/4885AR 3782/4885SLC22A12 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.